Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 11, 2026

‘I had hoped to be retired’: 66-year-old still works 11-hour days with zero savings. Here’s how you can avoid this fate

View original at finance.yahoo.com
‘I had hoped to be retired’: 66-year-old still works 11-hour days with zero savings. Here’s how you can avoid this fate Photo: CBS News Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Only 43% of American adults could handle an unexpected $1,000 expense with their savings

    80% confidence

  • Employment rate for Americans 65+ has nearly doubled compared to 35 years ago

    80% confidence

  • She had hoped to be retired, playing piano and enjoying life

    80% confidence

  • Moby's stock recommendations have beaten the S&P 500 by almost 12% on average over four years across almost 400 stock picks

    80% confidence

  • Nearly half of U.S. women aged 55 to 66 have no personal retirement savings

    80% confidence

  • Gold could climb to $6,200 per ounce by the end of 2026

    80% confidence

  • Recommends saving enough to cover three to six months of living expenses for emergencies

    80% confidence

  • She works 11-hour days across two jobs with no savings, 401(k), or emergency fund

    80% confidence

  • Financial situation has been life-threatening

    80% confidence

  • Approximately one in five Americans aged 65 and over were employed in 2023

    80% confidence

  • 47% of men aged 55 to 66 have no personal retirement savings

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
‘I had hoped to be retired’: 66-year-old still works 11-hour days with zero savings. Here’s how you can avoid this fate — Source | Via News | ViaNews EU